|
- 2017
替加环素治疗重症患者呼吸机相关性肺炎
|
Abstract:
[1] | 谭建龙, 张卫东, 柳威, 等. 替加环素治疗多或泛耐药鲍曼不动杆菌肺炎的疗效观察[J]. 中国呼吸与危重监护杂志, 2013, 12(6): 581-585. TAN Jianlong, ZHANG Weidong, LIU Wei, et al. Clinical experience with tigecycline in the treatment of multi/extensively drug-resistant acinetobacter baumannii pneumonia[J]. Chinese Journal of Respiratory and Critical Care Medicine, 2013, 12(6): 581-585. |
[2] | Montravers P, Dupont H, Bedos JP, et al. Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting[J]. Intensive Care Med, 2014, 40(7): 988-997. |
[3] | Cai Y, Bai N, Liu X, et al. Tigecycline: Alone or in combination?[J]. Infect Dis(Lond), 2016, 48(7): 491-502. |
[4] | Bhavnani SM, Rubino CM, Hammel JP. et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline[J]. Antimicrob Agents Chemother, 2012, 56(2): 1065-1072. |
[5] | Eckmann C, Heizmann WR, Leitner E, et al. Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice[J]. Chemotherapy, 2011, 57(4): 275-284. |
[6] | Ellis-Grosse EJ, Babinchak T, Dartois N, et al. Tigecycline 300 cSSSI study group; Tigecycline 305 cSSSI study group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam[J]. Clin Infect Dis, 2005, 41(5): 341-353. |
[7] | Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia[J]. Diagn Microbiol Infect Dis, 2008, 61(3): 329-338. |
[8] | Shin JA, Chang YS, Kim HJ, et al. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection[J]. Yonsei Med, 2012, 53(5): 974-984. |
[9] | 管向东, 刘紫锰. 2013《呼吸机相关性肺炎诊断、预防和治疗指南》—目标性治疗的解读[J]. 中华医学杂志, 2014, 94(5): 333-334. |
[10] | Cai Y, Wang R, Liang B, et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease[J]. Antimicrob Agents Chemother, 2011, 55(3): 1162-1172. |
[11] | 中华医学会重症医学分会. 呼吸机相关性肺炎诊断、预防和治疗指南(2013)[J]. 中华内科杂志, 2013, 52(6): 524-543. |
[12] | 《抗菌药物临床试验技术指导原则》写作组. 抗菌药物临床试验技术指导原则[J]. 中国临床药理学杂志, 2014(9): 844-856. |
[13] | Stein GE, Babinchak T. Tigecycline: an update[J]. Diagn Microbiol Infect Dis, 2013, 75(4): 331-336. |
[14] | 朱任媛, 张小江, 杨启文, 等. 卫生部全国细菌耐药监测网2011年ICU来源细菌耐药监测[J]. 中国临床药理学杂志, 2012, 28(12): 905-909. ZHU Renyuan, ZHANG Xiaojiang, YANG Qiwen, et al. Ministry of health national antimicrobial resistance investigation net annual report of 2011: surveillance of antimicrobial resistance in bacteria from intensive care units[J]. The Chinese Journal of Clinical Pharmacology, 2012, 28(12): 905-909. |
[15] | Wu Yuhong, Shao Zonghong. High-dosage tigecycline for Stenotrophomonas maltophilia bacteremia[J]. Chin Med J(Engl), 2014, 127(17): 3199. |
[16] | Moya Cordero P, Ruiz-Aragón J, Molina Linde JM, et al. Evaluation of the efficacy and safety of tigecycline for treatment of respiratory tract infections. Systematic review of literature[J]. Revista Chilena De Infectologia, 2013, 30(6): 591-597. |